We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Enhanced Silencing Longevity of siRNA

By Biotechdaily staff writers
Posted on 15 Jan 2004
A proprietary form of small interfering RNA (siRNA) called siStable siRNA has been modified to significantly enhance stability, potency, and silencing longevity while decreasing cellular toxicity.

In comparative cell culture studies, siStable siRNA maintains full silencing potency after seven days. More...
In human serum, where nucleases break down unmodified siRNA, siStable siRNA half-life is increased more than 500-fold from minutes to over 85 hours. The siStable siRNA modifications also alter siRNA processing within the cell, increasing gene silencing potency and specificity. These data were presented at the annual meeting of the American Society for Cell Biology in San Francisco (CA, USA).

To develop siStable siRNA, scientists at Dharmacon, Inc. (Lafayette, CO, USA) chemically modified the siRNA strands in a novel and proprietary manner. The new product builds on previous modifications contained in Dharmacon's On-Target siRNA that inactivate the siRNA sense strand, completely eliminating its potential role in causing off-target silencing. Microarray gene expression analysis studies to date have shown no cellular toxicity from use of siStable siRNA.

"We are committed to working with life science researchers to make the potential advantages of RNAi widely available for an increasing range of biomedical applications,” said Stephen A. Scaringe, Ph.D., co-chairman and chief scientific officer at Dharmacon.




Related Links:
Dharmacon

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.